Traders Purchase Large Volume of Call Options on Cypherpunk Technologies (NASDAQ:CYPH)

Key Points

• Options activity surged: Traders purchased 4,594 CYPH call options, approximately 89% above the typical volume of 2,430 contracts.
• Analyst sentiment remains mixed: Cypherpunk Technologies has a consensus “Hold” rating and a $1.60 price target, despite Cantor Fitzgerald maintaining an “Overweight” rating.
• Shares rose sharply: CYPH climbed $0.40 to $3.03 in heavy trading, while institutional investors own 30.46% of the company and an insider recently sold 20,000 shares.

Cypherpunk Technologies (NASDAQ:CYPH - Get Free Report) was the target of unusually large options trading activity on Wednesday. Stock traders bought 4,594 call options on the company. This is an increase of approximately 89% compared to the typical volume of 2,430 call options.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Cypherpunk Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, August 17th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $1.60 price objective on shares of Cypherpunk Technologies in a research note on Thursday, August 27th. Finally, Wall Street Zen upgraded shares of Cypherpunk Technologies from a "sell" rating to a "hold" rating in a report on Saturday, July 4th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Cypherpunk Technologies presently has a consensus rating of "Hold" and a consensus price target of $1.60.

Insider Buying and Selling

In other news, Director Thomas Dietz sold 20,000 shares of the stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $1.72, for a total value of $34,400.00. Following the transaction, the director owned 132,500 shares of the company's stock, valued at $227,900. This represents a 13.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CYPH. Acadian Asset Management LLC grew its stake in Cypherpunk Technologies by 470.4% during the 1st quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company's stock worth $389,000 after buying an additional 1,056,047 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new stake in Cypherpunk Technologies in the fourth quarter valued at about $56,000. HighTower Advisors LLC acquired a new stake in Cypherpunk Technologies in the fourth quarter worth about $59,000. Simplify Asset Management Inc. acquired a new stake in Cypherpunk Technologies in the fourth quarter worth about $2,172,000. Finally, Texas Capital Bank Wealth Management Services Inc acquired a new stake in Cypherpunk Technologies in the fourth quarter worth about $121,000. Hedge funds and other institutional investors own 30.46% of the company's stock.

Cypherpunk Technologies Price Performance

Shares of CYPH stock traded up $0.40 during trading hours on Wednesday, reaching $3.03. 10,077,202 shares of the company traded hands, compared to its average volume of 4,130,036. The firm has a 50-day moving average price of $1.02 and a 200 day moving average price of $0.90. The company has a market cap of $326.51 million, a P/E ratio of 5.41 and a beta of 0.33. Cypherpunk Technologies has a 12-month low of $0.28 and a 12-month high of $3.70.

Cypherpunk Technologies (NASDAQ:CYPH - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported $0.18 earnings per share for the quarter.

About Cypherpunk Technologies

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.